MX2021013123A - Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol. - Google Patents
Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol.Info
- Publication number
- MX2021013123A MX2021013123A MX2021013123A MX2021013123A MX2021013123A MX 2021013123 A MX2021013123 A MX 2021013123A MX 2021013123 A MX2021013123 A MX 2021013123A MX 2021013123 A MX2021013123 A MX 2021013123A MX 2021013123 A MX2021013123 A MX 2021013123A
- Authority
- MX
- Mexico
- Prior art keywords
- tramadol
- reducing
- pain
- treatment
- celecoxib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere al uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor, para prevenir el riesgo de adicción al tramadol, para el tratamiento del dolor y al mismo tiempo reducir la propensión al abuso del tramadol, para el tratamiento del dolor también reduciendo una incidencia de adicción al tramadol, para el tratamiento del dolor previniendo una adicción al tramadol, para el tratamiento del dolor en un paciente con adicción al tramadol o el riesgo de sufrirlo, para el tratamiento del dolor e inhibir, retrasar, reducir o revertir adicción al tramadol o para el tratamiento del dolor y reducción de la incidencia de adicción al tramadol .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382377 | 2019-05-14 | ||
PCT/EP2020/063250 WO2020229502A1 (en) | 2019-05-14 | 2020-05-13 | Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013123A true MX2021013123A (es) | 2021-11-18 |
Family
ID=66589491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013123A MX2021013123A (es) | 2019-05-14 | 2020-05-13 | Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230020469A1 (es) |
EP (1) | EP3968978A1 (es) |
JP (1) | JP2022533580A (es) |
KR (1) | KR20220008301A (es) |
CN (1) | CN113825501A (es) |
AU (1) | AU2020276711A1 (es) |
BR (1) | BR112021020893A2 (es) |
CA (1) | CA3137381A1 (es) |
CO (1) | CO2021016623A2 (es) |
IL (1) | IL287955A (es) |
MA (1) | MA55954A (es) |
MX (1) | MX2021013123A (es) |
SG (1) | SG11202111390TA (es) |
WO (1) | WO2020229502A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177215A1 (en) * | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177215A1 (en) * | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
SI2488169T1 (sl) * | 2009-10-16 | 2013-05-31 | Laboratorios Del Dr. Esteve, S.A. | Ko - kristali iz tramadola in koksibov |
MX2012003050A (es) * | 2009-10-16 | 2012-05-29 | Esteve Labor Dr | Co-cristales de tramadol y coxibs. |
EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
EP2392319A1 (en) * | 2010-06-04 | 2011-12-07 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
WO2018119033A1 (en) * | 2016-12-20 | 2018-06-28 | Cima Labs Inc. | Abuse-resistant and abuse-deterrent dosage forms |
-
2020
- 2020-05-13 MA MA055954A patent/MA55954A/fr unknown
- 2020-05-13 JP JP2021567069A patent/JP2022533580A/ja active Pending
- 2020-05-13 AU AU2020276711A patent/AU2020276711A1/en active Pending
- 2020-05-13 WO PCT/EP2020/063250 patent/WO2020229502A1/en unknown
- 2020-05-13 MX MX2021013123A patent/MX2021013123A/es unknown
- 2020-05-13 KR KR1020217040169A patent/KR20220008301A/ko unknown
- 2020-05-13 BR BR112021020893A patent/BR112021020893A2/pt unknown
- 2020-05-13 US US17/609,452 patent/US20230020469A1/en active Pending
- 2020-05-13 EP EP20724510.1A patent/EP3968978A1/en active Pending
- 2020-05-13 CN CN202080035879.7A patent/CN113825501A/zh active Pending
- 2020-05-13 CA CA3137381A patent/CA3137381A1/en active Pending
- 2020-05-13 SG SG11202111390TA patent/SG11202111390TA/en unknown
- 2020-05-14 US US15/931,681 patent/US20200360306A1/en not_active Abandoned
-
2021
- 2021-11-09 IL IL287955A patent/IL287955A/en unknown
- 2021-12-07 CO CONC2021/0016623A patent/CO2021016623A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020229502A1 (en) | 2020-11-19 |
SG11202111390TA (en) | 2021-11-29 |
CA3137381A1 (en) | 2020-11-19 |
IL287955A (en) | 2022-01-01 |
MA55954A (fr) | 2022-03-23 |
US20230020469A1 (en) | 2023-01-19 |
US20200360306A1 (en) | 2020-11-19 |
JP2022533580A (ja) | 2022-07-25 |
CN113825501A (zh) | 2021-12-21 |
CO2021016623A2 (es) | 2022-01-17 |
AU2020276711A1 (en) | 2021-11-18 |
EP3968978A1 (en) | 2022-03-23 |
KR20220008301A (ko) | 2022-01-20 |
BR112021020893A2 (pt) | 2022-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
EP4253412A3 (en) | Inhibition of cytokine-induced sh2 protein in nk cells | |
GEP20247617B (en) | Methods and compositions for treating sleep apnea | |
WO2016070051A3 (en) | Combination therapy for treatment of disease | |
MX338447B (es) | Tratamiento para diabetes en pacientes inapropirados para terapia con metformina. | |
JOP20200035A1 (ar) | تركيبات حمض أميني لعلاج الإصابات العصبية | |
PH12018502491A1 (en) | Cancer treatments | |
MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
MY189342A (en) | Treatment and prevention of the common cold using povidone-iodine | |
MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
MX2021013123A (es) | Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol. | |
MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. | |
EP3821884A4 (en) | USE OF A COMPOUND IN A MEDICATION FOR THE PREVENTION, TREATMENT OR RELIEF OF PAIN | |
PH12021551365A1 (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. | |
CA3091759A1 (en) | Methods and compositions for maintaining opioid efficacy in the treatment of pain | |
WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. | |
EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
WO2020097442A3 (en) | Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases | |
IL282718A (en) | Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases | |
GB201900633D0 (en) | Compositions and methods for treating, preventing or ameliorating pain |